Communicating with Your Dermatopathologist: Biopsy Technique, Nail Unit Sampling, and Modern Melanocytic Pathology

Conclusions

• Clear communication between clinicians and dermatopathologists improves diagnostic accuracy by ensuring the right specimen, medium, and requisition information are provided.
• Choosing the biopsy type that matches the suspected pathologic process is essential to avoid sampling errors and loss of clinically important depth or architecture.
• Nail unit biopsies require careful technique and specimen handling, including preserving orientation and accounting for decalcification effects on downstream pathology.
• The requisition form and specimen context matter greatly because incomplete or misleading clinical information can undermine the pathology interpretation.
• MPATH-Dx addresses poor interobserver agreement in melanocytic lesions by replacing subjective atypia grading with a standardized risk-based classification system.
• This new melanocytic framework is intended to reduce overtreatment, especially for low-risk lesions with positive margins that may not need re-excision if adequately sampled.
• Melanoma in situ and certain intermediate melanocytic tumors are treated as low-to-non-negligible risk lesions rather than uniformly as overt malignancy.
• Ancillary stains such as SOX10 and PRAME improve diagnostic support, but they still require clinicopathologic correlation and are not definitive in isolation.
• PRAME is useful for distinguishing melanoma from nevus in many cases, yet it can be positive in ambiguous lesions and should not replace expert interpretation.
• Commercial gene-expression profiling and other molecular tests are promising, but for melanoma they are not yet sufficiently integrated into guidelines to provide broadly actionable prognostic information beyond standard clinicopathologic factors.
• Gene-expression profiling may help stratify squamous cell carcinoma risk, but broader validation and prospective integration are still needed.
• Next-generation sequencing and multiplex immunohistochemistry are expanding dermatopathology’s ability to characterize tumors, microenvironments, and therapeutic targets.
• Despite technological advances, expert judgment, direct pathologist consultation, and careful correlation with the clinical picture remain indispensable in difficult cases.
• AI and predictive analytics are emerging as supportive tools in dermatopathology, with potential for high-accuracy detection and workflow assistance, but they are adjuncts rather than replacements for specialist communication.